Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
65847-85-0
Molecular formula
C19H20F3N3O3
Molecular weight
395.4 g/mol
Drug class
Non-steroidal anti-inflammatory drug (NSAID)flufenamic-acid prodrug
Mechanism of action
Morniflumate is an ester prodrug hydrolysed to flufenamic acid, a fenamate NSAID that inhibits cyclooxygenase-mediated prostaglandin synthesis and reduces inflammation, pain and fever.
Indications / reported uses
Symptomatic treatment of pain and inflammatory conditions, including musculoskeletal and ENT inflammatory disorders, in countries where morniflumate is authorised.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Morniflumate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Morniflumate Permitted Daily Exposure (PDE) report (the Morniflumate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Morniflumate Occupational Exposure Limit (OEL) report (the Morniflumate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.